Cross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination-Reference-Cited by-同舟云学术

Cross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination

Published:2021-10-08 Issue:6564 Volume:374 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Loyal Lucie¹²^ORCID,Braun Julian¹²^ORCID,Henze Larissa¹²^ORCID,Kruse Beate¹²,Dingeldey Manuela¹²^ORCID,Reimer Ulf³^ORCID,Kern Florian³⁴^ORCID,Schwarz Tatjana⁵^ORCID,Mangold Maike¹²^ORCID,Unger Clara¹²^ORCID,Dörfler Friederike¹,Kadler Shirin¹⁶^ORCID,Rosowski Jennifer¹⁶,Gürcan Kübrah¹⁶,Uyar-Aydin Zehra¹⁶^ORCID,Frentsch Marco⁷⁸,Kurth Florian⁹¹⁰^ORCID,Schnatbaum Karsten³^ORCID,Eckey Maren³^ORCID,Hippenstiel Stefan⁹^ORCID,Hocke Andreas⁹^ORCID,Müller Marcel A.²⁵¹¹^ORCID,Sawitzki Birgit¹²^ORCID,Miltenyi Stefan¹³,Paul Friedemann¹⁴¹⁵^ORCID,Mall Marcus A.¹⁶¹⁷^ORCID,Wenschuh Holger³,Voigt Sebastian¹⁸¹⁹^ORCID,Drosten Christian²⁵¹¹^ORCID,Lauster Roland¹⁶,Lachman Nils²⁰^ORCID,Sander Leif-Erik⁹^ORCID,Corman Victor M.²⁵¹¹^ORCID,Röhmel Jobst¹⁶^ORCID,Meyer-Arndt Lil¹²¹⁴¹⁵²¹^ORCID,Thiel Andreas¹²^ORCID,Giesecke-Thiel Claudia²²^ORCID

Affiliation:

1. Si-M/“Der Simulierte Mensch,” a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany.

2. Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

3. JPT Peptide Technologies GmbH, Berlin, Germany.

4. Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK.

5. Institute of Virology, Charité – Universitätsmedizin Berlin, Berlin, Germany.

6. Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany.

7. Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany.

8. Therapy-Induced Remodeling in Immuno-Oncology, Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany.

9. Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany.

10. Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

11. German Centre for Infection Research (DZIF), Partner Site Charité, Berlin, Germany.

12. Institute of Medical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany.

13. Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany.

14. Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, and Charité – Universitätsmedizin Berlin, Berlin, Germany.

15. Clinical Neuroimmunology, NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, Berlin, Germany.

16. Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany.

17. German Center for Lung Research, Associated Partner, Berlin, Germany.

18. Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany.

19. Institute for Virology, Universitätsklinikum Essen, Essen, Germany.

20. Institute for Transfusion Medicine, Tissue Typing Laboratory, Charité – Universitätsmedizin Berlin, Berlin, Germany.

21. Department of Neurology and Experimental Neurology, Charité – Universitätsmedizin Berlin, Berlin, Germany.

22. Max Planck Institute for Molecular Genetics, Berlin, Germany.

Abstract

Cross-reactive T cells aid in the fight There is mounting evidence that immunological memory after infection with seasonal human coronaviruses (hCoVs) contributes to cross-protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Loyal et al . identified a universal immunodominant coronavirus peptide found within the fusion peptide domain of coronavirus spike protein. This peptide is recognized by CD4 + T cells in 20% of unexposed individuals, more than 50% of SARS-CoV-2 convalescents, and 97% of subjects treated with the Pfizer–BioNTech COVID-19 vaccine. Although ubiquitous, these coronavirus-reactive T cells decreased with age, which may explain in part the increased susceptibility of elderly people to COVID-19. —STS

Funder

Deutsches Zentrum für Infektionsforschung

Horizon 2020 Framework Programme

Deutsche Forschungsgemeinschaft

Horizon 2020

Federal Ministry of Health, Germany

Deutsche Zentrum für Lungenforschung

German Ministry of Research

Federal Ministery of Health

VMC RECAST to BS MAMa JR VMC LES and NaFoUniMedCovid19 COVIM FKZ

Publisher

American Association for the Advancement of Science (AAAS)